US4349684A - N-Substituted ω-(2-oxo-4-imidazolin-1-yl) alcanoic acids and salts and esters thereof - Google Patents
N-Substituted ω-(2-oxo-4-imidazolin-1-yl) alcanoic acids and salts and esters thereof Download PDFInfo
- Publication number
- US4349684A US4349684A US06/318,962 US31896281A US4349684A US 4349684 A US4349684 A US 4349684A US 31896281 A US31896281 A US 31896281A US 4349684 A US4349684 A US 4349684A
- Authority
- US
- United States
- Prior art keywords
- imidazolin
- oxo
- phenyl
- acid
- esters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention refers to new N-substituted ⁇ -(2-oxo-4-imidazolin-1-yl) alcanoic acid derivatives having the general formula I ##STR2## wherein
- n is an integer ranging from 1 to 10, preferably ranging from 6 to 8,
- R 1 represents hydrogen, an alkali metal ion or a straight or branched hydrocarbon group having from 1 to 6 carbon atoms or the benzyl group,
- R 2 is --(CH 2 ) m --R, m being 0, 1 or 2,
- R, R 3 and R 4 which may be identical or different from each other, represent hydrogen (with the exception of R if m is zero), the unsubstituted phenyl group or the phenyl group substituted by one or several identical or differing substituents selected from the group consisting of halogen (in particular chlorine or fluorine), CH 3 --, CH 3 O--, --CF 3 , at least one of R, R 3 and R 4 being a phenyl group or the phenyl group substituted by one or several identical or differing substituents selected from the group of halogen, --CH 3 , CH 3 O--, --CF 3 .
- halogen in particular chlorine or fluorine
- the present invention further refers to processes for producing the same.
- the new compounds show interesting pharmacological properties such as antiallergic, antiasthmatic, antithrombotic, antiarteriosklerotic and antiinflammatory properties. They furthermore show antagonistic activity in respect to some physiological processes regulated by PAF (platelet activation factor) as well as excellent compatibility by the stomach and may therefor in particular used for the treatment of thrombotic, allergic, asthmatic and arteriosclerotic as well as inflammatory deseases with at the same time favourable gastrointestinal properties. Furthermore, the compounds of formula I have a low toxicity. They furthermore may be produced in combination with anticoagulantia, in particular with heparin and heparinates.
- the new N-substituted ⁇ -(2-oxo-4-imidazolin-1-yl)alcanoic acid derivatives in the form of the free acids or of the salts thereof with pharmacologically compatible bases or as esters thereof may be used as active ingredient in drugs together with usual carrier materials or diluents.
- the compounds of general formula I according to the present invention are used in dosages ranging from 0.1 to 100 mg/kg, in particular 1 to 50 mg/kg.
- the compounds according to the present invention are produced according to the invention in that a 4-imidazolin-2-one of the general formula II ##STR3## wherein R 2 , R 3 and R 4 have the same meaning as in formula I, which may be produced by known processes usual in the chemistry of heterocyclic compounds from isocyanates and ⁇ -aminoketones or, respectively, from benzoketones with substituted ureas, is subjected to reaction with an alkylating agent of the general formula III
- n and R 1 have the same meaning as in formula I and X is a halogen atom, in an organic solvent such as acetone, methyl ethyl ketone, dimethylformamide with the addition of an auxiliary base such as sodium hydride, possibly in the presence of an alkali metal iodide as catalyst.
- the compounds of formula I may also be produced by subjecting an ⁇ -(2-oxo-4-imidazolin-1-yl)-alcanoic acid or a derivative thereof having the general formula IV ##STR4## wherein R 1 , R 3 and R 4 have the same meaning as in formula I, which may be produced by the synthesis described in the German patent application No. P 29 50 478.7, to reaction with an alkylating agent of formula V
- Y has the same meaning of X in formula III or Y is another usual favourable group to be split off, for instance the N 2 -group or the radical of a sulphuric acid ester, in particular of a sulphuric acid lower alkyl ester.
- Substituted phenyl groups R 2 (or, respectively, R), R 3 and R 4 are for instance: 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2.5-dimethoxyphenyl, 3.4-dimethoxyphenyl, 3.4.5-trimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl.
- Alkylating agents of formula III are for instance the esters of the following ⁇ -halogeno alcanoic acids:
- chloroacetic acid bromoacetic acid, iodoacetic acid, 3-chloropropionic acid, 3-bromopropionic acid, 3-iodopropionic acid, 4-chlorobutyric acid, 4-bromobutyric acid, 4-iodobutyric acid, 5-chlorovaleric acid, 5-bromovaleric acid, 5-iodovaleric acid, 6-chlorocapronic acid, 6-bromocapronic acid, 6-iodocapronic acid, 7-chloroenanthic acid, 7-bromoenanthic acid, 7-iodoenanthic acid, 8-chlorocaprylic acid, 8-bromocaprylic acid, 8-iodocaprylic acid, 9-chloropelargonic acid, 9-bromopelargonic acid, 9-iodopelargonic acid, 10-chlorocaprinic acid, 10-bromocaprinic acid, 10-iodocaprinic acid, 11-
- alkylating agents of formula V are:
- the alcohols R 1 OH preferably are such alcohols with straight or secondary branched saturated hydrocarbon groups with 1 to 6 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, pentanol, hexanol as well as benzylalcohols.
- the new compounds of formula I may be administered orally or by injection or rectally as suitable pharmaceutical products which may be solid or liquid, in the form of suspensions or solutions.
- suitable pharmaceutical products are tablets, powders, capsules, granules, ampoules, sirups and suppositories.
- the given melting points have been determined on a BUCHI 510 melting point determination apparatus and are not corrected.
- the IR-spektra have been determined on a PERKIN ELMER 257 and the mass spektra on a VARIAN MAT-311 A (70 eV).
- reaction product is diluted with water, extracted with ether, the ether phase is washed consequetively with water, with 5% NaHCO 3 solution and again with water.
- ethereal solution is dried over Na 2 SO 4 , the solvent is distilled off in a vacuum and the residue is purified chromatographically on silicic acid gel using chloroform as eluant.
- the product is obtained as described in example 1 from 1.35 g NaJ (80% suspension in mineral oil), 12.2 g of 1-(4-chlorophenyl)-5-phenyl-4-imidazolin-2-one, 100 cc. of DMF, 8.7 g of 7-chloroenanthic acid ethyl ester and 1.35 g of NaJ.
- Eluant in chromatographic purification hexane/ethyl acetate.
- the product is obtained as described in example 1 from 2.1 g of NaH (80% suspension in mineral oil), 18.5 g of 1-ethyl-4.5-diphenyl-4-imidazolin-2-one, 140 cc. of DMF, 13.5 g of 7-chloroenanthic acid ethyl ester and 2.1 g of NaJ.
- the product is produced as described in example 1 from 2.34 g of NaH (80% suspension in mineral oil), 18.5 g of 1.5-diphenyl-4-imidazolin-2-one, 160 cc. of DMF, 18.5 g of 8-bromocaprylic acid methyl ester and 2.34 g of NaJ.
- the product is produced as described in example 1 from 2.4 g of NaH (80% suspension in mineral oil), 21.6 g of 1-(4-chlorophenyl)-5-phenyl-4-imidazolin-2-one, 160 cc. of DMF, 19.0 g of 8-bromocaprylic acid methyl ester and 2.4 g of NaJ.
- the product is produced as described in example 1 from 1.41 g of NaH (80% suspension in mineral oil), 14.3 g of 5-phenyl-1-(3-trifluoromethylphenyl)-4-imidazolin-2-one, 100 cc. of DMF, 11.1 g of 8-bromocaprylic acid methyl ester and 1.41 g of NaJ.
- the product is produced as described in example 1 from 2.4 g of NaH (80% suspension in mineral oil), 21.3 g of 1-(4-methoxyphenyl)-5-phenyl-4-imidazolin-2-one, 160 cc. of DMF 19 g of 8-bromocaprylic acid methyl ester and 2.4 g of NaJ. Eluant in chromatographic purification: hexane/ethyl acetate.
- the product is produced as described in example 1 from 2.25 g of NaH (80% suspension in mineral oil), 18.7 g of 1-(4-methylphenyl)-5-phenyl-4-imidazolin-2-one, 150 cc. of DMF, 17.8 g of 8-bromocaprylic acid methyl ester and 2.25 g of NaJ.
- the product is product as described in example 1 from 2.16 g of NaH (80% suspension in mineral oil), 18.3 g of 1-(4-Fluorophenyl)-5-phenyl-4-imidazolin-2-one, 150 cc. of DMF, 17.1 g of 8-bromocaprylic acid methyl ester and 2.16 g of NaJ.
- the product is produced as described in example 1 from 1.05 g of NaH (80% suspension in mineral oil), 9.5 g of 5-(4-chlorophenyl)-1-phenyl-4-imidazolin-2-one, 70 cc. of DMF, 8.3 g of 8-bromocaprylic acid methyl ester and 1.05 g of NaJ.
- the product is produced as described in example 1 from 1.8 g of NaH (80% suspension in mineral oil), 15 g of 1-benzyl-5-phenyl-4-imidazolin-2-one, 120 cc. of DMF, 14.2 g of 8-bromocaprylic acid methyl ester and 1.8 g of NaJ.
- the product is produced as described in example 1 from 1.2 g of NaH (80% suspension in mineral oil), 12 g of 1.4.5-triphenyl-4-imidazolin-2-one, 80 cc. of DMF, 9.5 g of 8-bromocaprylic acid methyl ester and 1.2 g of NaJ.
- the product is produced as described in example 1 from 0.63 of NaH (80% suspension in mineral oil), 5.9 g of 4.5-bis-(2-fluorophenyl)-1-methyl-4-imidazolin-2-one, 40 cc. of DMF, 5.0 g of 8-bromo caprylic methyl ester and 0.63 g of NaJ.
- the product is produced as described in example 1 from 2.4 g of NaH (80% suspension in mineral oil), 20 g of 4.5-diphenyl-1-methyl-4-imidazolin-2-one, 160 cc. of DMF, 19 g of 8-bromocaprylic acid methyl ester and 2.4 g of NaJ.
- the product is produced as described in example 1 from 1.35 g of NaH (80% suspension in mineral oil), 12.2 g of 1-(4-chlorophenyl)-5-phenyl-4-imidazolin-2-one, 90 cc. of DMF, 11.3 g of 9-bromo-nonanic acid methyl ester and 1.35 g of NaJ.
- the product is produced as described in example 1 from 0.45 g of NaH (80% suspension in mineral oil), 4 g of 1-ethyl-4.5-diphenyl-4-imidazolin-2-one, 30 cc. of DMF, 4.2 g of 11-bromoundecanoic acid methyl ester and 0.45 g of NaJ.
- the oil is dissolved in a small amount of chloroform, the chloroform phase is washed with water several times and is finally extracted with 5% soda lye.
- the soda lye extract is washed with chloroform, the aqueous solution is acidified with dilute hydrochloric acid and is separated from the acid precipitated as an oil. Purification occurs by chromatography on silicic acid gel using a mixture of chloroform and methanol as eluant.
- the product is produced as described in example 18 from 13.5 g of 7-[3-(4-chlorophenyl)-2-oxo-4-phenyl-4-imidazolin-1-yl] enanthic acid ethel ester, 1.28 g of NaOH in 60 cc. of ethanol.
- the product is produced as described in example 18 from 12.3 g of 7-(3-ethyl-4.5-diphenyl-2-oxo-4-imidazolin-1-yl) enanthic acid ethyl ester and 1.16 g of NaOH in 60 cc. of ethanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 8.2 g of 8-(3.4-diphenyl-2-oxo-4-imidazolin-1-yl) caprylic acid methyl ester and 0.84 g of NaOH in 20 cc. of ethanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 20 g of 8-[3-(4-chlorophenyl)-2-oxo-4-phenyl-4-imidazolin-1-yl] caprylic acid methyl ester and 1.88 g of NaOH in 100 cc. of methanol. Further purification by chromatography on silicic acid gel using a mixture of hexane annd ethyl acetate as eluant.
- the product is produced as described in example 18 from 6.9 g of 8-[2-oxo-4-phenyl-3-(3-trifluoromethyl-phenyl)-4-imidazolin-1-yl] caprylic acid methyl ester and 0.66 g of NaOH in 30 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 18.8 g of 8-[3-(4-methoxyphenyl)-2-oxo-4-phenyl-4-imidazolin-1-yl] caprylic acid methyl ester and 2.12 g of NaOH in 100 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 18.1 g of 8-[3-(4-methylphenyl)-2-oxo-4-phenyl-4-imidazolin-1-yl] caprylic acid methyl ester and 1.8 g of NaOH in 90 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 16.4 g of 8-[3-(4-fluorophenyl)-2-oxo-4-phenyl-4-imidazolin-1-yl] caprylic acid methyl ester and 1.6 g of NaOH in 80 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 6.1 g of 8-[4-(4-chlorophenyl)-2-oxo-3-phenyl-4-imidazolin-1-yl] caprylic acid ethyl ester and 0.56 g of NaOH in 30 cc. of methanol. The product is finally boiled in a small amount of ether, filtered off with suction and dried.
- the product is produced as described in example 18 from 20.3 g of 8-(3-benzyl-2-oxo-4-phenyl-4-imidazolin-1-yl) caprylic acid methyl ester. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is prepared as described in example 18 from 7.5 g of 8-(2-oxo-3.4.5-triphenyl-4-imidazolin-1-yl)-caprylic acid methyl ester and 0.64 g of NaOH in 30 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 5.2 g of 8-[4.5-bis-(2-fluorophenyl)-3-methyl-2-oxo-4-imidazolin-1-yl] caprylic acid methyl ester and 0.53 g of NaOH in 25 cc. of methanol. Recrystallization from ether/hexane.
- the product is produced as described in example 18 from 17.5 g of 8-(4.5-diphenyl-3-methyl-2-oxo-4-imidazolin-1-yl) caprylic acid methyl ester and 2.1 g of NaOH in 100 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is produced as described in example 18 from 4.4 g of 9-[3-(4-chlorophenyl)-2-oxo-4-phenyl-4-imidazolin-1-yl] pelargonic acid methyl ester and 0.4 g of NaOH in 20 cc. of methanol. Further purification by chromatography on silicic acid gel using chloroform as eluant.
- the product is prepared as described in Example 48 from 1.5 g of 8-(4.5-diphenyl-3-methyl-2-oxo-4-midazolin-1-yl) caprylic acid, 0.55 g of thionyl chloride and 0.37 g of benzyl alcohol.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803042466 DE3042466A1 (de) | 1980-11-11 | 1980-11-11 | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
DE3042466 | 1980-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
US4349684A true US4349684A (en) | 1982-09-14 |
Family
ID=6116469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/318,962 Expired - Fee Related US4349684A (en) | 1980-11-11 | 1981-11-06 | N-Substituted ω-(2-oxo-4-imidazolin-1-yl) alcanoic acids and salts and esters thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US4349684A (fr) |
EP (1) | EP0051829B1 (fr) |
JP (1) | JPS57108073A (fr) |
AT (1) | ATE10626T1 (fr) |
DE (1) | DE3042466A1 (fr) |
DK (1) | DK495781A (fr) |
GR (1) | GR74703B (fr) |
IE (1) | IE52079B1 (fr) |
ZA (1) | ZA817696B (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0396973A1 (fr) * | 1989-04-26 | 1990-11-14 | Mitsubishi Kasei Corporation | Dérivés de 4-imidazolines et leur utilisation comme préparation de composés pharmaceutiques |
US5389666A (en) * | 1991-12-27 | 1995-02-14 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
US20070087998A1 (en) * | 2005-08-18 | 2007-04-19 | Weiwen Ying | Imidazole compounds that modulate HSP90 activity |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3228271A1 (de) * | 1982-07-29 | 1984-02-02 | A. Nattermann & Cie GmbH, 5000 Köln | Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
DE3323870A1 (de) * | 1983-07-02 | 1985-01-03 | A. Nattermann & Cie GmbH, 5000 Köln | Neue imidazol-2-ylthioalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
US4598149A (en) * | 1984-03-02 | 1986-07-01 | Merck & Co., Inc. | 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents |
NO890522L (no) * | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte imidazolinoner og imidazolinthioner. |
GB9019839D0 (en) * | 1990-09-11 | 1990-10-24 | Smith Kline French Lab | Compounds |
GB9019840D0 (en) * | 1990-09-11 | 1990-10-24 | Smith Kline French Lab | Compounds |
WO1995029163A1 (fr) * | 1994-04-27 | 1995-11-02 | Nippon Soda Co., Ltd. | Derive d'imidazole et procede de production de ce derive |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
ES2243016T3 (es) * | 1997-12-17 | 2005-11-16 | MERCK & CO., INC. | Antagonistas de receptores de integrinas. |
JP2003510360A (ja) * | 1999-10-04 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
RS56312B1 (sr) | 2010-02-27 | 2017-12-29 | Bayer Ip Gmbh | Ariltriazoloni spojeni sa bis-arilom i njihova upotreba |
DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
SG11201703199UA (en) | 2014-11-03 | 2017-05-30 | Bayer Pharma AG | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905996A (en) * | 1972-08-04 | 1975-09-16 | Roussel Uclaf | Imidazolidones |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2713431A1 (de) * | 1977-03-26 | 1978-09-28 | Bayer Ag | Verfahren zur herstellung von diacylierten 4-imidazolinonen-2 und deren verwendung fuer cycloadditionen |
DE2934746A1 (de) | 1979-08-28 | 1981-03-19 | A. Nattermann & Cie GmbH, 5000 Köln | Oxoimidazolinalkansaeuren, deren salze und ester sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE2950478A1 (de) | 1979-12-14 | 1981-06-19 | A. Nattermann & Cie GmbH, 5000 Köln | 4,5-diaryl-4-imidazolin-2-on-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
-
1980
- 1980-11-11 DE DE19803042466 patent/DE3042466A1/de not_active Withdrawn
-
1981
- 1981-10-29 AT AT81109294T patent/ATE10626T1/de not_active IP Right Cessation
- 1981-10-29 EP EP81109294A patent/EP0051829B1/fr not_active Expired
- 1981-11-02 IE IE2565/81A patent/IE52079B1/en unknown
- 1981-11-03 GR GR66407A patent/GR74703B/el unknown
- 1981-11-06 US US06/318,962 patent/US4349684A/en not_active Expired - Fee Related
- 1981-11-06 ZA ZA817696A patent/ZA817696B/xx unknown
- 1981-11-09 DK DK495781A patent/DK495781A/da not_active Application Discontinuation
- 1981-11-10 JP JP56179139A patent/JPS57108073A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905996A (en) * | 1972-08-04 | 1975-09-16 | Roussel Uclaf | Imidazolidones |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0396973A1 (fr) * | 1989-04-26 | 1990-11-14 | Mitsubishi Kasei Corporation | Dérivés de 4-imidazolines et leur utilisation comme préparation de composés pharmaceutiques |
US5116858A (en) * | 1989-04-26 | 1992-05-26 | Mitsubishi Kasei Corporation | 4-imidazoline derivatives |
US5389666A (en) * | 1991-12-27 | 1995-02-14 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
US5589496A (en) * | 1991-12-27 | 1996-12-31 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor agonist activity |
US5849919A (en) * | 1991-12-27 | 1998-12-15 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity |
US5962439A (en) * | 1991-12-27 | 1999-10-05 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
US20070087998A1 (en) * | 2005-08-18 | 2007-04-19 | Weiwen Ying | Imidazole compounds that modulate HSP90 activity |
US8629285B2 (en) | 2005-08-18 | 2014-01-14 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
US9156794B2 (en) | 2005-08-18 | 2015-10-13 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
Also Published As
Publication number | Publication date |
---|---|
JPS57108073A (en) | 1982-07-05 |
GR74703B (fr) | 1984-07-05 |
ZA817696B (en) | 1982-10-27 |
DE3042466A1 (de) | 1982-06-16 |
EP0051829A1 (fr) | 1982-05-19 |
EP0051829B1 (fr) | 1984-12-05 |
DK495781A (da) | 1982-05-12 |
ATE10626T1 (de) | 1984-12-15 |
IE52079B1 (en) | 1987-06-10 |
IE812565L (en) | 1982-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4349684A (en) | N-Substituted ω-(2-oxo-4-imidazolin-1-yl) alcanoic acids and salts and esters thereof | |
EP0104342B1 (fr) | Acides triphénylimidazolyloxyalcanoiques et leurs dérivés, procédé de leur préparation et compositions pharmaceutiques les contenant | |
US3821249A (en) | Dibenzothiazefin derivatives | |
US4954642A (en) | Forskolin compounds | |
JPH0214352B2 (fr) | ||
US4654358A (en) | 1,4,5-triphenylimidazol-2-yl mercapto alkanoic acids, useful against inflammation and diseases responding to lipid lowering | |
US5112972A (en) | Synthesis of chroman derivatives | |
US4377695A (en) | ω-(2-Oxo-benzazolinyl)-alkanoic acid derivatives | |
US4578467A (en) | Process for the preparation of 1-pyridyl-alkyl-4-aryl piperazines which are useful as antihypertensive compounds, their separation into the respective optical antipodes, and the stereoisomeric compounds so obtained | |
US5112839A (en) | Chroman derivatives | |
US4539326A (en) | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents | |
EP0011447B1 (fr) | Dérivés de l'acide 1-benzyl-1,2,5,6-tétrahydropyridine-3-carboxylique et leurs sels, inhibant l'agglomération plaquettaire sanguine, compositions pharmaceutiques les contenant et procédés pour leur préparation | |
EP0149419B1 (fr) | Dérivés d'acyle-indoles et compositions pharmaceutiques les contenant | |
US5516917A (en) | Leukotriene B4 antagonists | |
US4064244A (en) | Organic compounds | |
JPH01319479A (ja) | 5―アミノメチル―2―フラノメタノールの新規な誘導体、その製造及び使用 | |
AU643125B2 (en) | Quinone derivatives | |
FI71733B (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva 3,6-substituerade 2-vinyl-kromoner | |
CS214806B2 (en) | Method of making the derivatives of the auron | |
US4158061A (en) | 2,9-Dioxatricyclo[4,3,1,03,7 ] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | |
CN111978264B (zh) | 一种地拉罗司的工业化生产方法 | |
EP0146102A2 (fr) | Procédé de préparation de dérivés de benzothiazine | |
EP0184058A2 (fr) | Procédé de préparation de dérivés de l'indole et leur utilisation | |
EP0013726B1 (fr) | Dérivés d'acide indanyloxamique, leur préparation et préparations pharmaceutiques les contenant | |
DE3128277A1 (de) | (omega)-(5-(1-imidazolylmethyl)-thien-2-y1)-alkancarbonsaeuren und deren derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: A. NATTERMANN & CIE GMBH, NATTERMANNALLEE 1, D-500 Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:LAUTENSCHLAGER, HANS-HEINER;BETZING, HANS;STOLL, BRIGITTE;AND OTHERS;REEL/FRAME:004001/0499 Effective date: 19820507 Owner name: A. NATTERMANN & CIE GMBH, NATTERMANNALLEE 1, D-500 Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAUTENSCHLAGER, HANS-HEINER;BETZING, HANS;STOLL, BRIGITTE;AND OTHERS;REEL/FRAME:004001/0499 Effective date: 19820507 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19860914 |